Skip to Main Content

Filter:

New Drug Reviews

1 Results

Pharmacotherapy New drug review
Fidaxomicin: The Newest Addition to the Armamentarium Against Clostridium difficile Infections
Clinical Therapeutics
Vol. 34Issue 1p1–13Published in issue: January, 2012
- Jason W. Lancaster
- S. James Matthews
Cited in Scopus: 48
Fidaxomicin, a macrolide antibiotic, was the first medication for the management of Clostridium difficile infections (CDI) to be approved by the US Food and Drug Administration in more than 20 years.

Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.

RELX